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Objective: To determine if recombinant human bone morphogenetic protein-2 (rhBMP-2) has biological effects on the
invasiveness of human oral squamous cell carcinoma (OSCCA) cell lines.
Study Design: Laboratory investigation using six human OSCCA cell lines, with three cell lines having baseline gene
expression of BMP-2 and three cell lines without baseline gene expression of BMP-2.
Methods: The invasiveness of each cell line was measured using a matrigel invasion assay with or without stimulation
by rhBMP-2. A tumor metastasis quantitative PCR array was used to establish whether observed findings from the invasion
assay correlated to changes in gene expression.
Results: There was a significant increase in tumor cell invasion in response to rhBMP-2 in all BMP-2 positive cell lines
but no change in the cell lines that did not express the BMP-2 gene. Quantitative PCR revealed that changes in gene expres-
sion were distinctly different based on the baseline gene expression of BMP-2 and favored a more metastatic genotype in the
BMP-2-positive cells.
Conclusions: Recombinant human BMP-2 has an adverse biological effect on invasiveness of human OSCCA cell lines in
vitro. This adverse effect is dependent on the baseline gene expression of BMP-2. Changes in expression of genes involved
with tumor metastasis correlated to the invasion assay findings. These data raise concern for the safe application of rhBMP-2
for reconstruction of bone defects in oral cancer patients.
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INTRODUCTION
Human recombinant bone morphogenetic protein-2
(rhBMP-2) is a FDA-approved device for maxillary sinus
floor and alveolar ridge augmentation. Based on this
approval for use in orodental defects in addition to abun-
dant preclinical data, rhBMP-2 has now been reported
for use in segmental bone defects throughout the head
and neck region.1,2 As knowledge, technology, and expe-
rience advance in this area, there will be an inevitable
paradigm shift in reconstructive techniques from current
therapies using autologous bone grafts toward tissue en-
gineering using BMPs.3
There are several limitations with the use of
rhBMP-2 in craniofacial defects. One of the contraindica-
tions includes use in the vicinity of a resected tumor or
in patients undergoing treatment for malignancy. Such
use is currently contraindicated due to the unknown
effects of this growth factor on malignancies. This is a
significant consideration because the majority of seg-
mental bone defects in the head and neck region are
caused by resection of oral squamous cell carcinomas
(OSCCA). Our previous data showed that rhBMP-2 did
not have any adverse effects on proliferation or angio-
genesis in OSCCA in vitro.4 However, it has been
reported that increased BMP-2 gene expression is associ-
ated with regional metastasis from OSCCA.5 This could
be related to BMP effects on invasiveness or migration
ability of OSCCA cells, as has been shown for prostate,
colon, and lung carcinomas.6–8
The primary objective of this study was to deter-
mine if rhBMP-2 has biological effects on the
invasiveness of OSCCA. Secondary objectives were to
determine if any observed effects correlate with baseline
gene expression of BMP-2, and to establish if rhBMP-2
treatment changes expression profiles for genes involved
with tumor metastasis.
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MATERIALS AND METHODS
Cell Culture and Media
Human oral squamous carcinoma cell lines UPCI:SCC032
(retromolar trigone), UPCI:SCC056 (oral tongue), and UPCI:
SCC182 (retromolar trigone) were provided by Dr. Susanne M.
Gollin (University of Pittsburgh, PA). Cells were maintained in
MEM medium (GIBCO-Invitrogene, Carlsbad, CA) supplemented
with Earle’s salt, L-glutamine, 1 NEAA, 10% fetal bovine
serum (FBS) and gentamicin. Human oral squamous carcinoma
cell lines UMSCC-1 (floor of mouth), UMSCC-14A (floor of
mouth), and UMSCC-74A (oral tongue) were provided by from
Dr. Thomas E. Carey (University of Michigan at Ann Arbor, MI).
The cells were grown in DMEM (Mediatech Inc., Manasses, VA)
supplemented with 4.5 g/L glucose, L-glutamine, 10% FBS, 1
NEAA, and penicillin–streptomycin. Cultures were maintained
at 37C in an atmosphere of 5% CO2.
BMP-2 Gene Expression Analysis
Total RNA was isolated by TRIzol Reagent (Invitrogene,
Carlsbad, CA) according to manufacture’s protocol. Reverse tran-
scription to produce first-strand cDNA was performed with 2 lg of
total RNA by High-Capacity cDNA Reverse Transcription kit with
RNase inhibitor (Applied Biosystems, Foster City, CA) in accord-
ance with the manufacturer’s protocols. The BMP-2 transcript
was amplified from the cDNA by conventional PCR using gene-
specific primers: forward primer (50-CGAGGTCCTGAGCGAGTT
CGAG-30) and the reverse primer (50-TGGCAGTAAAAGGCGTGA
TACC-30); amplicon ¼ 837 bp; 35 cycles; cycle profile: 1 minute at
94C, 1 minute at 60C, 1 minute at 72C.9 The following GAPDH
gene specific primers were used: forward primer (50-ACCACAG
TCCATGCCATCAC-30) and the reverse primer (50-TCCACCAC
CCTGTTGCTGTA-30); amplicon ¼ 451 bp; 24 cycles; cycle profile:
30 seconds at 94C, 30 seconds at 55C, 30 seconds at 72C.10
Human normal oral mucosa was used as negative control, and
MG-63, an osteosarcoma-derived osteoblastic cell line was used as
positive control.11,12 Each sample was tested in duplicate in three
independent experimental runs.
Invasion Assay
Invasion assays were performed in BD BioCoat FluoroBlok
Tumor Invasion System (BD Biosciences, Bedford, MA) according
to the manufacturer’s manual. This system consists of the 24-
multiwell insert plate with an 8 micron pore size PET membrane
that has been uniformly coated with BD Matrigel Matrix. Tumor
cells were grown on 10-cm plates at the confluency of 70–90%
and stained overnight with 7.5 lg/mL of BD DiIC12 Fluorescent
Dye in OPTIMEM medium (GIBCO-Invitrogene). On the follow-
ing day, prelabeled cells were seeded to the top chamber at a
density of 1.65–5.0  105 cells per well. OPTIMEM was used as
a conditional medium. In the experimental wells rhBMP-2 (Cat:
B3555. Sigma-Aldrich, St. Louis, MO) was added to the top and
bottom chamber to the final concentration of 100 ng/mL. The 5%
FBS in basal medium was used as a chemoattractant. The real-
time fluorescence signals were detected by Synergy HT Multi-
Detection Microplate Reader (Bio-Tek Instruments, Inc.,
Winooski, VT). Plate Reader was custom set up according to BD
Biosciences technical bulletin #436 for a nonstandard 24-well
plate dimension. Optic were set at excitation: 530/25, emission:
590/30 at the bottom reading position. Quantitative readings
were done at 12 hours, 15 hours, 17 hours, and 19 hours after
stimulation. Data were normalized on Blank-a chamber without
cells, and Background- chambers with a cells and medium only.
All experiments were done in triplicate.
An inverted fluorescent microscope/camera Nikon Eclipse
TE2000-U was used to observe the cells on the membrane, and
capture fluorescent images. AnalySIS software was utilized for
handling and analysis of digital-microscopy images.
Quantitative PCR Array
Tumor cell lines were treated with 100 ng/mL of rhBMP-2
for 48 hours in OPTIMEM medium, control cells without rhBMP-
2 were incubated for the same period of time. Total RNA was iso-
lated by RNeasy Mini Kit (Qiagen, Valencia, CA) with addition of
DNase I treatment step. Reverse transcription of 2.5 lg of total
RNA was done by High-Capacity cDNA Reverse Transcription kit
with RNase inhibitor (Applied Biosystems). All real-time PCR
reactions were performed using an ABI Gene Amp 5700 Sequence
Detection System (Perkin-Elmer Applied Biosystems, Foster City,
CA). Instrument-specific RT2 Real-Time SYBR Green/Rox PCR
master mix and custom 96-well Human RT2 Profiler PCR Array
Human Tumor Metastasis plates containing predispensed gene-
specific primer sets were designed by SABiosciences (Frederick,
MD). This PCR Array is specifically designed with 84 genes
known to be involved in tumor metastasis. Two representative cell
lines were tested; UMSCC-1 (BMP-2 negative gene expression),
and UMSCC-74A (BMP-2 positive gene expression). A singleplex
reaction mix was prepared according to the manufacturer’s proto-
col. The thermal cycling conditions included an initial
denaturation step at 95C for 10 minutes, 40 cycles at 95C for 15
seconds, and 60C for 1 minute. To compare gene expressions
between samples, the threshold cycle (CT) was normalized using
the mean CT for reference genes. The RT
2 Profiler PCR Array
Data Analysis software from SABiosciences (http://sabiosciences.
com/pcr/arrayanalysis.php) based on the 2DDCT method was used
to compare treatment and control and to determine fold changes
in gene expression levels and statistical significance of these
changes. Mean values from the three independent experiments
were used in calculations. Each 96-well plate included five house-
keeping gene panel (B2M, HPRT1, RPL13A, GAPDH, and
b-Actin) to normalize PCR Array data and several controls:
Genomic DNA Control (specifically detects nontranscribed
genomic DNA contamination), Reverse Transcription Control
(tests the efficiency of first strand kit), and Positive PCR Control
(tests the efficiency of the polymerase chain reaction itself).
Statistical Analysis
Fluorescent readings were log10 transformed as typically
done to minimize the scale effect and to improve fit of the models.
Statistical analysis was performed using the PROC GLIMMIX
procedure in SAS 9.1 (SAS Institute, Cary, NC). To evaluate differ-
ences in invasive activity, the following mixed models were used
for each cell line: Log10(Fluorescence) ¼ Treatment þ Time þ
Treatment*Time þ e, where Treatment  N(0, r2Treatment) is the
effect of the BMP-2 treatment, Time  N(0, r2Time) is the time effect,
Treatment*Time  N(0, r2TT) is the effect of the treatment by time
interaction, and e  N(0, r2R) is the iid random error. The covariance
structure was modeled with the sp(pow) option that uses the aniso-
tropic power law appropriate for correlations declining as a function
of time and nonequal spacing between time points. The P-values at
or below the .05 level were considered significant.
RESULTS
BMP-2 Gene Expression in Human
OSCCA Cell Lines
RT-PCR was used to determine baseline BMP-2 gene
expression in six oral carcinoma cell lines. Three cell lines
were positive (UPCI:SCC 056, UMSCC-14A, UMSCC-74A)
and the other three were negative (UMSCC-1, UPCI:SCC
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032, UPCI:SCC 182) for BMP-2 expression (Fig. 1). All six
cell lines expressed the genes for all BMP-receptors (data
unpublished). These included BMPR-IA, BMPR-IB, BMPR-
II, ActR-I, ActR-IIA, and ActR-IIB.
Effect of rhBMP-2 on Invasiveness of
Human OSCCA Cell Lines
In response to treatment with rhBMP-2, there was a
significant increase in tumor cell invasion through the
Matrigel matrix in all BMP-2 positive cell lines. In con-
trast, no significant differences in invasiveness were
observed in the cell lines that did not express BMP-2
(Table I). Comparisons between tumor cells with and
without rhBMP-2 treatment were performed under stim-
ulation with 5% FBS, which served as a chemoattractant.
Dynamic changes of estimated means in treated and non-
treated cells are presented in the log10-scale graphs for
UMSCC-74A (Fig. 2B) and UPCI:SCC 182 (Fig. 2D) cell
lines. To determine the extent to which rhBMP-2 alone
could promote migration of tumor cells through a collagen
matrix, rhBMP-2 was added to the bottom chamber with-
out FBS. Only one cell line, UMSCC-74A, demonstrated
increased invasive potential in the presence of BMP-2
and without chemoattractant (Fig. 2A).
Gene Expression Changes in Response
to rhBMP-2
The Human Tumor Metastasis PCR Array was uti-
lized for quantitative real-time PCR. Results for UMSCC-
74A (positive BMP-2 gene expression) and UMSCC-1 (neg-
ative BMP-2 gene expression) are summarized in Table II.
Changes in gene expression favored a more metastatic ge-
notype in the BMP-2 positive cell line as opposed to the
BMP-2 negative cell line. In particular, changes in IL1b,
MTSS1, and TIMP-2 were positively correlated with the
invasion assay findings of increased invasiveness for
UMSCC-74A. MTSS1 and KISS1 are metastasis suppres-
sor genes that were both upregulated in UMSCC-1.
DISCUSSION
Tissue invasion is one of the six acquired capabilities
of cancer cells as described by Hanahan and Weinberg.13
This in vitro study demonstrated that rhBMP-2 promotes
the invasiveness of several human OSCCA cell lines, and
that this biologic effect is dependent, in part, on the base-
line gene expression of BMP-2. Specifically, this effect
was only observed for cell lines that demonstrated gene
expression of BMP-2. For the cell lines that did not
express BMP-2, there did not appear to be any effect
from the exogenous exposure to rhBMP-2. This cannot be
explained by differences in expression for the BMP-recep-
tors, because all these cell lines also express these genes.
The finding that baseline BMP-2 expression level influen-
ces the biological behavior is not unique to this study.14,15
To determine if there were any molecular changes
that correlated with the invasion assay findings, a real-
time quantitative PCR array that included genes known
to be involved with tumor metastasis was used on repre-
sentative cell lines that expressed (UMCCC-74A) or did
not express (UMSCC-1) BMP-2. In response to treatment
with rhBMP-2, the Metastasis suppressor 1 (MTSS1)
gene was significantly upregulated in UMSCC-1 and sig-
nificantly downregulated in UMSCC-74A. These findings
are consistent with the known function of this gene as a
metastasis suppressor, and suggests that it might be a
key modulator of invasive behavior of OSCCA.16 Overex-
pression of MTSS1 has been shown to significantly
suppress the invasive, migratory, growth, and adherence
properties of human breast cancer cell lines.16 Downregu-
lation of MTSS1 is also associated with nodal metastasis
and poor survival in patients with gastric cancer.17
Another metastasis suppressor, KISS1, was upregu-
lated in UMSCC-1 in response to rhBMP-2. KISS1
encodes the protein metastin, which is a G-protein
coupled receptor ligand for GPR54.18 This gene product
was initially described as a metastasis suppressor for
melanoma, but more recently elevated expression has
been shown to be a favorable prognostic factor for non-
small cell lung cancer and pancreatic cancer.19,20
The IL-1b gene was upregulated in UMSCC-74A in
response to rhBMP-2. This finding is consistent with
other published data showing the involvement of this
cytokine in tumor invasiveness and metastasis. Interleu-
kin-1 expression at the site of tumor development
enhances the expression of adhesion molecules on endo-
thelial malignant cells, and facilitates the invasion of
malignant cells into the circulation.21 For IL-1b knock-
out mice, local tumors or lung metastasis of B16
melanoma cells were not observed compared with wild
type.22 These effects were not restricted to the
Fig. 1. BMP-2 gene expression in cell lines. RT-PCR experiments
shown for normal human oral mucosa (negative control), MG-63
(positive control), and six oral squamous carcinoma cell lines.
TABLE I.







UPCI:SCC 032  .0543
UPCI:SCC 182  .4959
UMSCC-14A þ <.0001
UMSCC-74A þ .0041
UPCI:SCC 056 þ .0024
The fluorescent readings between rhBMP-2 treated and nontreated
cell lines were compared. P-values for the treatment effect are shown. P-
values <.05 were considered significant.
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melanoma model, but were also observed in DA/3 mam-
mary and prostate cancer cell models.
Interestingly, matrix metalloproteases (MMPs) were
found to be upregulated in the cell line that did not ex-
hibit increased invasiveness (MMP-3, MMP-10), whereas
these genes were found to be downregulated in the cell
line that demonstrated increased invasive behavior
(MMP-9, MMP-11). These findings seem counterintuitive
based on the general concept that MMPs mediate tumor
progression and metastasis.23 There is evidence in the
literature, however, that MMPs also have a protective
role in tumor progression.24 The MMP functions in vivo
are reliant on complex interactions between tumor cells
and the stroma.23 Our in vitro findings suggest that fur-
ther mechanistic studies are needed to determine
interactions between the BMP-2 signaling pathway and
MMPs.
For the invasion assay, experiments were not per-
formed to determine whether the findings were
dependent on a dose response to rhBMP-2. The dose
used for these experiments was a standard dose used in
other published in vitro studies.8,25 Another limitation is
the absence of a treatment group with an antagonist of
the BMP-2 pathway to see if the findings in the BMP-2-
positive cells can be inhibited. Prior data has already
shown that noggin or siRNA was able to inhibit the abil-
ity of rhBMP-2 to stimulate the migration of A549 lung
carcinoma cells or liver cancer cells, respectively.8,26
Last, only one cell line was used for each group (BMP-2-
positive vs. BMP-2-negative gene expression) for the
quantitative PCR array. We chose these representative
cell lines to generate hypotheses for future studies.
Our in vitro quantitative PCR data and invasion
assay analysis could not adequately answer all the
Fig. 2. Invasion assay. Images of oral carcinoma cell lines with positive (UMSCC-74A) (A) and negative (UPCI:SCC 182) (C) levels of BMP-2
mRNA expression were taken at 19 hours after stimulation (magnification 15). The respective dynamic profiles of invasive activity repre-
sented by log10 of fluorescence levels (means of three independent measurements) are shown on B and D. Error bars correspond to stand-
ard deviations for each time point and treatment.
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questions concerning invasive phenotype in OSCCA
tumors. More detailed protein analysis and in vivo stud-
ies are required. However, the complexity and diversity of
BMP receptors and their signal transduction mechanisms
make it likely that BMP-2 will exert a variety of interde-
pendent actions in tumor invasion and progression.
CONCLUSION
Recombinant human BMP-2 has an adverse biologi-
cal effect on invasiveness of human OSCCA cell lines in
vitro. This adverse effect appears to be dependent on the
baseline gene expression of BMP-2. We also detected
changes in expression of genes involved with tumor me-
tastasis that correlated to the invasion assay findings.
Collectively, these data raise concern for the safe
application of rhBMP-2 for reconstruction of bone defects
in oral cancer patients and support the need for in depth
in vivo analysis of these potential untoward effects.
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MMP-11 1.79 .0161 MMP-10 2.87 .0087
MCAM 1.76 .0043 MMP-3 2.35 .0029
PLAUR 1.59 .0041 KISS1 1.87 .0043
TIMP-2 1.55 .0095 MTSS1 1.52 .0023
Fold changes in expression levels of genes after rhBMP-2 treatment
for two representative OSCCA cell lines. Only genes showing statistically
significant changes (p-values < .05) are shown.
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